Summary of findings table ‐ Emicizumab prophylaxis vs on‐demand therapy
Serious adverse events · people with inhibitors
Summary of findings table ‐ Emicizumab prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
- Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B 2024 · Cochrane Headline outcomes onlyRR 1.32 [0.48, 3.63]1 study · 52 participantsModerate